| Dr Matthew A Eaton, DO | |
|
2401 W University Ave, Muncie, IN 47303-3428 | |
| (765) 747-3111 | |
| (317) 962-5492 |
| Full Name | Dr Matthew A Eaton |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 2401 W University Ave, Muncie, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205247384 | NPI | - | NPPES |
| 264430H33 | Other | IN | MEDICARE PTAN |
| 300005773 | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Arnett Hospital | Lafayette, IN | Hospital |
| Riverview Health | Noblesville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverview Hospital | 1153216627 | 145 |
| Indiana University Health Care Associates Inc | 5799755864 | 882 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Riverview Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609074921 PECOS PAC ID: 1153216627 Enrollment ID: O20040216000572 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Lafayette Emergency Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861447211 PECOS PAC ID: 9830189240 Enrollment ID: O20040517001198 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Marion General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528099041 PECOS PAC ID: 9133023625 Enrollment ID: O20040524001483 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Emergency Professionals Of Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013951219 PECOS PAC ID: 4183604150 Enrollment ID: O20040721000612 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Entity Name | Cep America Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285103671 PECOS PAC ID: 6608056171 Enrollment ID: O20190214000611 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew A Eaton, DO 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Matthew A Eaton, DO 2401 W University Ave, Muncie, IN 47303-3428 Ph: (765) 747-3111 |
News Archive
Environmental factors may be a contributory cause in the development of some childhood cancers, leading scientists have revealed.
On the eve of the first National ADHD Awareness Day, the first biological assessment tool for Attention Deficit Hyperactivity Disorder is being introduced in Denver.
A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.
Researchers at NYU Langone Medical Center may have discovered a new targeted intervention for Barth Syndrome (BTHS).
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 4 days ago
Milissa Ann Eley, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 S Madison St, Muncie, IN 47305 Phone: 765-286-7000 Fax: 765-213-2769 | |
Mr. Ervin A Hunt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-4236 Fax: 765-741-2961 | |
Dr. Alyssa Ashley Hunter, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-741-1515 | |
Darrell R Hofer, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3807 S Madison St, Muncie, IN 47302 Phone: 765-751-3300 Fax: 765-751-3313 | |
Chandler Scott Brobst, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2598 W White River Blvd, Muncie, IN 47303 Phone: 765-702-2817 Fax: 765-222-2198 | |
Dr. Jason P Medler, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3241 |